201 – 300 of 302
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
EVOLUTION OF A beta 42 AND A beta 40 LEVELS AND A beta 42/A beta 40 RATIO IN PLASMA DURING PROGRESSION OF ALZHEIMER'S DISEASE: A MULTICENTER ASSESSMENT
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
(
- Contribution to journal › Article
-
Mark
White matter hyperintensities and medial temporal lobe atrophy in clinical subtypes of mild cognitive impairment: the DESCRIPA study
(
- Contribution to journal › Article
-
Mark
Concentrations of Metals, beta-Amyloid and Tau-Markers in Cerebrospinal Fluid in Patients with Alzheimer's Disease
(
- Contribution to journal › Article
-
Mark
Risk Factors for Nursing Home Placement in Cholinesterase Inhibitor Treated Naturalistic Alzheimer Patients.
2009) 9th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD)(
- Contribution to conference › Poster
-
Mark
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
(
- Contribution to journal › Article
-
Mark
Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?
(
- Contribution to journal › Article
-
Mark
Interleukin-6 Is Elevated in the Cerebrospinal Fluid of Suicide Attempters and Related to Symptom Severity.
(
- Contribution to journal › Article
-
Mark
Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests.
(
- Contribution to journal › Article
-
Mark
Cerebrospinal Fluid Total Tau Is Associated with Shorter Survival in Dementia with Lewy Bodies.
(
- Contribution to journal › Article
- 2008
-
Mark
Electroencephalogram variability in dementia with lewy bodies, Alzheimer's disease and controls.
(
- Contribution to journal › Article
-
Mark
Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Effects of a goal-oriented rehabilitation program in mild cognitive impairment: A pilot study
(
- Contribution to journal › Article
-
Mark
Cube Copying Test in Combination with rCBF or CSF Abeta(42)Predicts Development of Alzheimer's Disease.
(
- Contribution to journal › Article
-
Mark
Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease
(
- Contribution to journal › Article
-
Mark
Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides
(
- Contribution to journal › Article
-
Mark
Development of screening guidelines and clinical criteria for predementia Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Predicting Long-Term Cognitive Outcome with New Regression Models in Donepezil-Treated Alzheimer Patients in a Naturalistic Setting.
(
- Contribution to journal › Article
-
Mark
The period of hypotension following orthostatic challenge is prolonged in dementia with Lewy bodies.
(
- Contribution to journal › Article
-
Mark
Association of complement factor HY402H gene polymorphism with Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
C4BP binds also to dead cells outside the blood compartment
(
- Contribution to journal › Published meeting abstract
-
Mark
Usefulness of computed tomography linear measurements in diagnosing Alzheimer's disease.
(
- Contribution to journal › Article
-
Mark
C4b-binding protein in Alzheimer's disease: Binding to Abeta(1-42) and to dead cells.
(
- Contribution to journal › Article
-
Mark
CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies.
2008) In Neurobiology of Aging(
- Contribution to journal › Article
-
Mark
The usefulness of cube copying for evaluating treatment of Alzheimer's disease.
(
- Contribution to journal › Article
- 2007
-
Mark
Longitudinal stability of CSF biomarkers in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
Prediction of Alzheimer's Disease Using the CSF Abeta42/Abeta40 Ratio in Patients with Mild Cognitive Impairment.
(
- Contribution to journal › Article
-
Mark
Soluble adhesion molecules and angiotensin-converting enzyme in dementia.
(
- Contribution to journal › Article
-
Mark
Associations between AQT processing speed and neuropsychological tests in neuropsychiatric patients
(
- Contribution to journal › Article
-
Mark
Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly
(
- Contribution to journal › Article
-
Mark
A quick test for cognitive speed: a measure of cognitive speed in dementia with lewy bodies.
(
- Contribution to journal › Article
-
Mark
Effects of Alzheimer's peptide and alpha 1-antichymotrypsin on astrocyte gene expression
(
- Contribution to journal › Article
-
Mark
Patients With Dementia With Lewy Bodies Have More Impaired Quality of Life Than Patients With Alzheimer Disease.
(
- Contribution to journal › Article
-
Mark
Patients with Lewy body dementia use more resources than those with Alzheimer's disease.
(
- Contribution to journal › Scientific review
-
Mark
Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies
(
- Contribution to journal › Article
-
Mark
Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
(
- Contribution to journal › Article
-
Mark
Alzheimer's disease - Safety and dropout in long-term galantamine treatment in a routine clinical setting
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Activities of daily living - Outcome during two years in galantamine treated Alzheimer patients
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Three-year outcome of Galantamine treatment in Alzheimer’s disease in a routine clinical setting.
2007) IPA (International Psychogeriatric Association) 2007 Osaka Silver Congress(
- Contribution to conference › Poster
-
Mark
Activities of Daily Living – Outcome During Three Years in Donepezil Treated Alzheimer Patients.
2007) IPA (International Psychogeriatric Association) 2007 Osaka Silver Congress(
- Contribution to conference › Poster
- 2006
-
Mark
Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study
(
- Contribution to journal › Article
-
Mark
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
(
- Contribution to journal › Article
-
Mark
Vagus nerve stimulation in patients with Alzheimer's disease: Additional follow-up results of a pilot study through 1 year.
(
- Contribution to journal › Article
-
Mark
Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment
(
- Contribution to journal › Article
-
Mark
CSF Biomarkers for Alzheimer's Disease: Levels of beta-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival.
(
- Contribution to journal › Article
-
Mark
New regression models for long-term cognitive change in Donepezil treated Alzheimer patients.
2006) 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
-
Mark
2-års resultat av rivastigmin (Exelon®) behandling vid Alzheimers sjukdom i klinisk vardag.
2006) Läkarstämman 2006(
- Contribution to conference › Poster
-
Mark
Om möss och människor. Inte givet att fynd hos alzheimermöss kan appliceras i klinisk verklighet
(
- Contribution to journal › Article
-
Mark
Demensvården behöver reformeras. Resurserna används inte optimalt - dags att evidensbasera vården
(
- Contribution to journal › Article
-
Mark
Two-year outcome of Galantamine treatment in Alzheimer’s disease in a routine clinical setting.
2006) 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy(
- Contribution to conference › Poster
- 2005
-
Mark
The transcobalamin 776C > G polymorphism may be a modifiable genetic risk factor for Alzheimer's disease
(
- Contribution to journal › Letter
-
Mark
Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF
(
- Contribution to journal › Article
-
Mark
Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Lower Gait Speed in Older Women with Dementia Compared with Controls.
(
- Contribution to journal › Article
-
Mark
Starka belägg för att proffsboxning leder till kroniska hjärnskador. Ju fler slag mot huvudet under en boxares karriär, desto större är risken
(
- Contribution to journal › Article
-
Mark
Analysis of the heterogeneity in treatment response to Donepezil in Alzheimer’s disease conclusions from the Swedish Alzheimer Treatment Study Group.
(
- Contribution to conference › Poster
- 2004
-
Mark
Regional Cerebral Blood Flow in Alzheimer's Disease: Classification and Analysis of Heterogeneity.
(
- Contribution to journal › Article
-
Mark
Multiple rapid automatic naming measures of cognition: Normal performance and effects of aging
(
- Contribution to journal › Article
-
Mark
Five-Year Outcome of Cholinergic Treatment of Alzheimer's Disease: Early Response Predicts Prolonged Time until Nursing Home Placement, but Does Not Alter Life Expectancy.
(
- Contribution to journal › Article
-
Mark
Clinical utility of color-form naming in Alzheimer's disease: Preliminary evidence
(
- Contribution to journal › Article
- 2003
-
Mark
Increased frequency of a new polymorphism in the cycle 2 (cdc2) gene in patients with Alzheimer's disease frontotemporal dementia
(
- Contribution to journal › Article
-
Mark
Cerebral pattern of pro- and anti-inflammatory cytokines in dementias
(
- Contribution to journal › Article
-
Mark
The Transcobalamin (TC) Codon 259 Genetic Polymorphism Influences Holo-TC Concentration in Cerebrospinal Fluid from Patients with Alzheimer Disease.
(
- Contribution to journal › Letter
-
Mark
Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients
(
- Contribution to journal › Article
-
Mark
Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease.
(
- Contribution to journal › Article
- 2002
-
Mark
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors
(
- Contribution to journal › Article
-
Mark
Parietal lobe: Activation in rapid, automatized naming by adults
(
- Contribution to journal › Article
-
Mark
Descriptive study and pharmacotherapeutic intervention in patients with epilepsy or Parkinson's disease at nursing homes in southern Sweden.
(
- Contribution to journal › Article
- 2001
-
Mark
Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Normal or Alzheimer's disease? - Automated interpretation of cerebral blood flow images using artificial neural networks
2001) Congress of the european association of nuclear medicine In European Journal Of Nuclear Medicine 28(8). p.1062-1062(
- Contribution to journal › Published meeting abstract
-
Mark
Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders
(
- Contribution to journal › Article
-
Mark
Decreased levels of intrathecal interleukin 1 receptor antagonist in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Both total and phosphorylated tau are increased in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype
(
- Contribution to journal › Article
-
Mark
Tacrine may alter APP-like protein levels in the lumbar CSF of Alzheimer patients
(
- Contribution to journal › Article
-
Mark
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice
(
- Contribution to journal › Article
- 2000
-
Mark
Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases
(
- Contribution to journal › Article
-
Mark
CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging
(
- Contribution to journal › Article
-
Mark
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma
(
- Contribution to journal › Article
-
Mark
TNF gene polymorphism and its relation to intracerebral production of TNFalpha and TNFbeta in AD
(
- Contribution to journal › Article
-
Mark
No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression
(
- Contribution to journal › Article
-
Mark
Measurement of apolipoprotein E (apoE) in cerebrospinal fluid
(
- Contribution to journal › Article
-
Mark
Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD
(
- Contribution to journal › Article
-
Mark
Nya rön om Alzheimers sjukdom: Gott hopp om att biokemiska markörer kan skärpa diagnostiken
(
- Contribution to journal › Article
- 1999
-
Mark
Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
(
- Contribution to journal › Article
- 1998
-
Mark
Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease
(
- Contribution to journal › Article
- 1997
-
Mark
The apolipoprotein E epsilon4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease
(
- Contribution to journal › Article
-
Mark
Somatostatin and neuropeptide Y in cerebrospinal fluid: correlations with severity of disease and clinical signs in Alzheimer's disease and frontotemporal dementia
(
- Contribution to journal › Article
- 1996
-
Mark
Correlation between clinical characteristics and cerebrospinal fluid neuropeptide Y levels in dementia of the Alzheimer type and frontotemporal dementia
(
- Contribution to journal › Article
- 1995
-
Mark
Long-term effects of tacrine on regional cerebral blood flow changes in Alzheimer's disease
(
- Contribution to journal › Article
- 1994
-
Mark
Tacrine treatment modifies cerebrospinal fluid neuropeptide levels in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Neuropsychological tests as discriminators between dementia of Alzheimer type and frontotemporal dementia
(
- Contribution to journal › Article
- 1993
-
Mark
Cortical blood flow during head-up postural change in subjects with orthostatic hypotension
1993) In Clinical autonomic research : official journal of the Clinical Autonomic Research Society 3(5). p.311-318(
- Contribution to journal › Article
-
Mark
Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration
(
- Contribution to journal › Article
-
Mark
Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG
(
- Contribution to journal › Article